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Classic genetics alone cannot explain the diversity of pheno-types within a population. Nor does classic genetics explain how, despite their identical DNA sequences, monozygotic twins1 or cloned animals2 can have 
different phenotypes and different susceptibilities to a disease. The concept of epi-
genetics offers a partial explanation of these phenomena. First introduced by C.H. 
Waddington in 1939 to name “the causal interactions between genes and their prod-
ucts, which bring the phenotype into being,”3 epigenetics was later defined as heri-
table changes in gene expression that are not due to any alteration in the DNA se-
quence.4
The best-known epigenetic marker is DNA methylation. The initial finding of 
global hypomethylation of DNA in human tumors5 was soon followed by the identifi-
cation of hypermethylated tumor-suppressor genes,6-11 and then, more recently, the 
discovery of inactivation of microRNA (miRNA) genes by DNA methylation.12,13 These 
and other demonstrations of how epigenetic changes can modify gene expression have 
led to human epigenome projects14 and epigenetic therapies.15 Moreover, we now 
know that DNA methylation occurs in a complex chromatin network and is influ-
enced by the modifications in histone structure that are commonly disrupted in cancer 
cells.16-19
Epigenetic research uses powerful techniques for the study of DNA methylation, 
such as sodium bisulfite modification associated with polymerase-chain-reaction pro-
cedures.20,21 Terms used in epigenetic research are defined in the Glossary. Compre-
hensive epigenomic techniques22 have yielded preliminary descriptions of the epi-
genomes of human cancer cells.23-25 This review summarizes new developments 
concerning hypermethylation of the promoter regions of tumor-suppressor genes26 
and describes possible applications of epigenetics to the treatment of patients with 
cancer.
Epigene tic Fe at ur es of a  Nor m a l Cel l
DNA methylation has critical roles in the control of gene activity and the architecture 
of the nucleus of the cell. In humans, DNA methylation occurs in cytosines that pre-
cede guanines; these are called dinucleotide CpGs.26,27 CpG sites are not randomly 
distributed in the genome; instead, there are CpG-rich regions known as CpG islands, 
which span the 5′ end of the regulatory region of many genes. These islands are usu-
ally not methylated in normal cells.26,27 The methylation of particular subgroups of 
promoter CpG islands can, however, be detected in normal tissues.
DNA methylation is one of the layers of control of certain tissue-specific genes, 
such as MASPIN, a member of the serum protease inhibitor family,28 and germ-line 
genes such as the MAGE genes, which are silent in almost all tissues except malig-
nant tumors.29 Genomic imprinting also requires DNA hypermethylation at one of 
the two parental alleles of a gene to ensure monoallelic expression,30 and a similar 
gene-dosage reduction is involved in X-chromosome inactivation in females.31 The 
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hypermethylation of repetitive genomic se-
quences probably prevents chromosomal insta-
bility, translocations, and gene disruption caused 
by the reactivation of transposable DNA sequenc-
es.32 Cells that lack the stabilizing effect of DNA 
methylation because they have spontaneous de-
fects in DNA methyltransferases (DNMTs)33 or 
experimentally disrupted DNMTs34 have promi-
nent nuclear abnormalities.
DNA methylation occurs in the context of 
chemical modifications of histone proteins.35 His-
tones are not merely DNA-packaging proteins, but 
molecular structures that participate in the regu-
lation of gene expression. They store epigenetic 
information through such post-translational mod-
ifications as lysine acetylation, arginine and lysine 
methylation, and serine phosphorylation. These 
modifications affect gene transcription and DNA 
repair. It has been proposed that distinct histone 
modifications form a “histone code.”36 Acetylation 
of histone lysines, for example, is generally associ-
ated with transcriptional activation.15,16 The func-
tional consequences of the methylation of histones 
depends on the type of residue — lysine (K) or 
arginine — and the specific site that the methyla-
tion modifies (e.g., K4, K9, or K20).15,16 Methyla-
tion of H3 at K4 is closely linked to transcriptional 
activation,37 whereas methylation of H3 at K9 or 
K27 and of H4 at K20 is associated with transcrip-
tional repression. What emerges from these find-
ings is a flexible but precise pattern of DNA meth-
ylation and histone modification that is essential 
for the physiologic activities of cells and tissues.
DNA H y pome th y l ation in T umor s
The low level of DNA methylation in tumors as 
compared with the level of DNA methylation in 
their normal-tissue counterparts was one of the 
first epigenetic alterations to be found in human 
cancer.5 The loss of methylation is mainly due to 
hypomethylation of repetitive DNA sequences and 
demethylation of coding regions and introns — 
regions of DNA that allow alternative versions of 
the messenger RNA (mRNA) that is transcribed 
from a gene.38 A recent large-scale study of DNA 
methylation with the use of genomic microarrays 
has detected extensive hypomethylated genomic re-
gions in gene-poor areas.24 During the develop-
ment of a neoplasm, the degree of hypomethylation 
of genomic DNA increases as the lesion progresses 
from a benign proliferation of cells to an invasive 
cancer39 (Fig. 1).
Three mechanisms have been proposed to ex-
Glossary
Acetylation: A reaction that introduces a functional acetyl group into an organic compound. Deacetylation is the remov-
al of the acetyl group. Acetylation is a post-translational chemical modification of histones, tubulins, and the tumor 
suppressor p53.
Bisulfite sequencing: The bisulfite treatment of DNA in order to determine its pattern of methylation. Treatment of 
DNA with bisulfite converts cytosine residues to uracil but leaves 5-methylcytosine residues unaffected.
Chromatin: The complex of DNA and protein that composes chromosomes. Chromatin packages DNA into a volume 
that fits into the nucleus, allows mitosis and meiosis, and controls gene expression. Changes in chromatin struc-
ture are affected by DNA methylation and histone modifications.
CpG islands: Regions in DNA that contain many adjacent cytosine and guanine nucleotides. The “p” in CpG refers to 
the phosphodiester bond between the cytosine and the guanine. These islands occur in approximately 40% of the 
promoters of human genes.
DNA methylation: The addition of a methyl group to DNA at the 5-carbon of the cytosine pyrimidine ring that precedes 
a guanine.
DNA methyltransferases: Family of enzymes that catalyze the transfer of a methyl group to DNA, using S-adenosyl-
methionine as the methyl donor.
Epigenome: The overall epigenetic state of a cell.
Genomic imprinting: The epigenetic marking of a locus on the basis of parental origin, which results in monoallelic 
gene expression.
Histone: The main protein components of chromatin. The core histones — H2A, H2B, H3, and H4 — assemble to 
form the nucleosome; each nucleosome winds around 146 base pairs of DNA. The linker histone H1 locks the DNA 
into place and allows the formation of a higher-order structure.
Histone deacetylase: A class of enzymes that remove acetyl groups from an N-acetyl-lysine amino acid on a histone.
Transposons: Sequences of DNA that can move around within the genome of a single cell. In this process, called trans-
position, the sequences can cause mutations and change the organization of DNA in the genome.
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plain the contribution of DNA hypomethylation 
to the development of a cancer cell: generation 
of chromosomal instability, reactivation of trans-
posable elements, and loss of imprinting. Under-
methylation of DNA can favor mitotic recombi-
nation, leading to deletions and translocations,40 
and it can also promote chromosomal rearrange-
ments. This mechanism was seen in experiments 
in which the depletion of DNA methylation by the 
disruption of DNMTs37 caused aneuploidy. Hypo-
methylation of DNA in malignant cells can reac-
tivate intragenomic endoparasitic DNA, such as L1 
(long interspersed nuclear elements), and Alu (re-
combinogenic sequence) repeats.32 These under-
methylated transposons can be transcribed or 
translocated to other genomic regions, thereby 
further disrupting the genome.
The loss of methyl groups from DNA can also 
disrupt genomic imprinting. In the hereditary 
Beckwith–Wiedemann syndrome (a syndrome 
characterized by exomphalos, macroglossia, and 
gigantism), for example, there is loss of imprint-
ing of IGF2 (the insulin-like growth factor gene) 
and an increased risk of cancer.41 Loss of imprint-
ing of IGF2 is also a risk factor for colorectal can-
cer,42,43 and disrupted genomic imprinting con-
tributes to the development of Wilms’ tumor.41 In 
animal models, mice with a loss of imprinting of 
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Figure 1. Epigenetic Alterations in Tumor Progression.
A multistage model of carcinogenesis in skin is shown. In conjunction with phenotypic cellular changes and the accumulation of genetic 
defects, there is a progressive loss of total DNA methylation content, an increased frequency of hypermethylated CpG islands, and an 
increased histone-modification imbalance in the development of the disease. H-ras denotes Harvey–ras oncogene, and 5mC 5-methyl-
cytosine.
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IGF244 or overall defects in imprinting45 have an 
increased risk of cancer. Normally, certain testis-
specific genes, genes that encode melanoma an-
tigens, or specific proliferation-linked genes38 are 
silent in somatic cells because promoter-region 
CpG islands are methylated. In some cancer cells, 
by contrast, these promoter regions undergo de-
methylation, and the usually repressed genes be-
come expressed. Two notable examples of the hy-
pomethylation mechanism are the activation of 
PAX2 (a gene that encodes a transcription factor 
involved in proliferation and other important ac-
tivities of cells) and the activation of the let-7a-3 
miRNA gene, which has been implicated in endo-
metrial and colon cancer.46,47
The hypomethylation of DNA can have unpre-
dictable effects. The progeny of a mouse deficient 
in DNA methylation and a Min mouse, which has 
a genetic defect in the adenomatous polyposis coli 
(APC) gene and is prone to colon adenoma, have 
fewer tumors than one would expect48; by con-
trast, another DNMT-defective mouse strain has 
an increased risk of lymphoma.49 Moreover, hy-
pomethylation suppresses the later stages of in-
testinal tumorigenesis48 but promotes early pre-
cancerous lesions in the colon and liver through 
genomic deletions.50
Inac ti vation of T umor-
Suppr essor Genes
Hypermethylation of the CpG islands in the pro-
moter regions of tumor-suppressor genes is a ma-
jor event in the origin of many cancers. The initial 
reports of hypermethylation of the CpG islands in 
the promoter region of the retinoblastoma tumor-
suppressor gene (Rb)6,7 were followed by the find-
ings that hypermethylation of the CpG island was 
a mechanism of inactivation of the tumor-suppres-
sor genes VHL (associated with von Hippel–Lindau 
disease), p16INK4a,8-11 hMLH1 (a homologue of MutL 
Escherichia coli),26 and BRCA1 (breast-cancer sus-
ceptibility gene 1).26,51
Hypermethylation of the CpG-island promoter 
can affect genes involved in the cell cycle, DNA 
repair, the metabolism of carcinogens, cell-to-cell 
interaction, apoptosis, and angiogenesis, all of 
which are involved in the development of can-
cer.22,26 Hypermethylation occurs at different stag-
es in the development of cancer and in different 
cellular networks, and it interacts with genetic le-
sions (Table 1). Such interactions can be seen when 
hypermethylation inactivates the CpG island of the 
promoter of the DNA-repair genes hMLH1, BRCA1, 
MGMT (O6-methylguanine–DNA methyltransfer-
ase), and the gene associated with Werner’s syn-
drome (WRN).26,51-53 In each case, silencing of the 
DNA-repair gene blocks the repair of genetic mis-
takes, thereby opening the way to neoplastic trans-
formation of the cell.
The profiles of hypermethylation of the CpG 
islands in tumor-suppressor genes are specific to 
the cancer type54,55 (Fig. 2 and Table 1). Each tu-
mor type can be assigned a specific, defining DNA 
“hypermethylome.” Such patterns of epigenetic 
inactivation occur not only in sporadic tumors but 
also in inherited cancer syndromes,56 in which 
hypermethylation can be the second lesion in 
Knudson’s two-hit model of how cancer devel-
ops.56,57 Recently devised epigenomic techniques 
have revealed maps of hypermethylation of the 
CpG islands that suggest the occurrence of 100 to 
400 hypermethylated CpG islands in the promoter 
regions of a given tumor.22
We still do not understand how CpG islands 
become hypermethylated in some types of cancer 
but not in others. Inactivation of a particular gene 
by methylation could give certain tumor types a 
growth advantage. CpG islands can have a loca-
tion within a particular nucleotide sequence that 
allows them to become hypermethylated,24 or they 
can be located in a chromosomal region that is 
subject to large-scale epigenetic dysregulation.22 In 
addition, there is a mechanism in which modifica-
tions of histones mark a gene for hypermethyl-
ation. This marking occurs in the binding of the 
methyltransferase enhancer of zeste drosophila 
homologue 2 (EZH2), a component of the poly-
comb family of gene-silencing proteins,58,59 to 
histones in stem cells with unmethylated gene 
promoters60-62 and in the histone-associated si-
lencing of p16INK4a in colon-cancer cells.63 
His t one Modific ations  
of C a ncer Cel l s
Mass spectrometry, the most reliable method for 
detecting changes in histones, is time-consuming 
and highly specialized.22 Moreover, histone mod-
ifications occur in different histone proteins, his-
tone variants (e.g., H3.3), and histone residues such 
as lysine, arginine, and serine. These modifications 
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also involve different chemical groups (e.g., methyl, 
acetyl, and phosphate) and have different degrees 
of methylation (e.g., monomethylation, dimethyl-
ation, and trimethylation). Acetylation and meth-
ylation of histones have direct effects on a variety 
of nuclear processes, including gene transcription, 
DNA repair, DNA replication, and the organiza-
tion of chromosomes. Generally, histone acety-
lation is associated with transcriptional activa-
tion,15,16 but the effect of histone methylation 
depends on the type of amino acid and its posi-
tion in the histone tail.15,16 The many permuta-
tions and combinations form a complex web of 
histone modifications.
Hypermethylation of the CpG islands in the 
promoter regions of tumor-suppressor genes in 
cancer cells is associated with a particular combi-
nation of histone markers: deacetylation of his-
tones H3 and H4, loss of H3K4 trimethylation, and 
gain of H3K9 methylation and H3K27 trimethyl-
ation.23,64 The presence of the hypo-acetylated and 
hypermethylated histones H3 and H465 silences 
certain genes with tumor-suppressor–like proper-
ties, such as p21WAF1, despite the absence of hyper-
methylation of the CpG island. In human tumors 
generally, modifications of histone H4 entail a loss 
of monoacetylated and trimethylated forms.18 
These changes appear early and accumulate dur-
Table 1. Epigenetic Aberrations among Different Tumor Types.*
Type of Cancer Epigenetic Disruption
Colon cancer CpG-island hypermethylation (hMLH1, p16INK4a, p14ARF, RARB2, SFRP1, and WRN), hyper-
methylation of miRNAs (miR-124a), global genomic hypomethylation, loss of imprinting of 
IGF2, mutations of histone modifiers (EP300 and HDAC2), diminished monoacetylated and 
trimethylated forms of histone H4
Breast cancer CpG-island hypermethylation (BRCA1, E-cadherin, TMS1, and estrogen receptor), global ge-
nomic hypomethylation
Lung cancer CpG-island hypermethylation (p16INK4a, DAPK, and RASSF1A), global genomic hypomethyl-
ation, genomic deletions of CBP and the chromatin-remodeling factor BRG1
Glioma CpG-island hypermethylation (DNA-repair enzyme MGMT, EMP3, and THBS1)
Leukemia CpG-island hypermethylation (p15INK4b, EXT1, and ID4), translocations of histone modifiers 
(CBP, MOZ, MORF, MLL1, MLL3, and NSD1)
Lymphoma CpG-island hypermethylation (p16INK4a, p73, and DNA-repair enzyme MGMT), diminished 
monoacetylated and trimethylated forms of histone H4
Bladder cancer CpG-island hypermethylation (p16INK4a and TPEF/HPP1), hypermethylation of miRNAs  
(miR-127), global genomic hypomethylation
Kidney cancer CpG-island hypermethylation (VHL), loss of imprinting of IGF2, global genomic hypomethylation
Prostate cancer CpG-island hypermethylation (GSTP1), gene amplification of polycomb histone methyltransfer-
ase EZH2, aberrant modification pattern of histones H3 and H4
Esophageal cancer CpG-island hypermethylation (p16INK4b and p14ARF), gene amplification of histone demethylase 
JMJD2C/GASC1
Stomach cancer CpG-island hypermethylation (hMLH1 and p14ARF)
Liver cancer CpG-island hypermethylation (SOCS1 and GSTP1), global genomic hypomethylation
Ovarian cancer CpG-island hypermethylation (BRCA1)
* BRCA1 denotes breast-cancer susceptibility gene 1, BRG1 BRM/SWI2-related gene 1, CBP cyclic AMP response-element–
binding protein (CREB)–binding protein, DAPK death-associated protein kinase, EMP3 epithelial membrane protein 3, 
EP300 E1A binding protein p300, EXT1 exostosin 1, EZH2 enhancer of zeste drosophila homologue 2, GSTP1 glutathi-
one S-transferase 1, HDAC2 histone deacetylase 2, hMLH1 homologue of MutL Escherichia coli, ID4 inhibitor of DNA 
binding 4, IGF2 insulin-like growth factor 2, JMJD2C/GASC1 Jumonji domain-containing protein 2C, MGMT O6-methyl-
guanine–DNA methyltransferase, MLL1 mixed-lineage leukemia 1, MLL3 mixed-lineage leukemia 3, MORF monocytic 
leukemia zinc finger protein–related factor, MOZ monocytic leukemia zinc finger, NSD1 nuclear receptor binding SET-
domain protein 1, RARβ2 retinoic acid receptor β 2, RASSF1A ras association domain family protein 1, SFRP1 secreted 
frizzled-related protein 1, SOCS1 suppressor of cytokine signaling 1, THBS1 thrombospondin 1, TMS1 target of methyl-
ation-induced silencing 1, TPEF/HPP1 hyperplastic polyposis gene 1, VHL von Hippel–Lindau disease, and WRN Werner’s 
syndrome.
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ing the development of the tumor18 (Fig. 1). The 
losses occur predominantly at the monoacetylated 
Lys16 and trimethylated Lys20 residues of histone 
H4 in association with hypomethylated repetitive 
DNA sequences.18 They have been found in breast 
and liver cancer.66,67 In prostate cancer, weak im-
munohistochemical staining of two histone mod-
ifications (the dimethylation of lysine 4 and the 
acetylation of lysine 18 of histone H3) has been 
proposed as a marker of a high risk of recur-
rence.19
There are also genetic lesions to consider in the 
aberrant epigenetic landscape of the cancer cell 
(Fig. 3 and Table 1). Expression patterns of his-
tone-modifying enzymes distinguish cancer tis-
sues from their normal counterparts, and they 
differ according to tumor type.68 In leukemias and 
sarcomas, chromosomal translocations that in-
volve histone-modifier genes, such as histone 
acetyltransferases (e.g., cyclic AMP response-ele-
ment-binding protein [CREB]–binding protein–
monocytic leukemia zinc finger [CBP-MOZ]) and 
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Figure 2. Profile of Hypermethylation of the CpG Island in the Promoter Region of Tumor-Suppressor Genes in Human Cancer.
Four tumor cells are shown undergoing transcriptional silencing by DNA hypermethylation of the regulatory regions of tumor-suppres-
sor genes. In colon cancer, entrance into the cell cycle occurs by means of p16INK4a methylation. In leukemia cells, p15INK4b methylation 
initiates proliferation. In breast-cancer cells, defects in DNA repair are related to methylation of BRCA1, and in glioma cells, methylation 
of O6-methylguanine–DNA methyltransferase (MGMT) initiates defects in DNA repair. Other depicted hypermethylated tumor-suppres-
sor genes are CDH1 (cadherin 1), CDH13 (cadherin 11), CRBP1 (cellular retinol binding protein 1), DKK-1 (dickkopf homologue 1), ER 
(estrogen receptor), GATA-4 (GATA-binding protein 4), GATA-5 (GATA-binding protein 5), HIC1 (hypermethylated in cancer 1), PR (pro-
gesterone receptor), PRLR (prolactin receptor), RARβ2 (retinoic acid receptor β 2), SLC5A8 (solute carrier family 5 iodide transporter 
member 8), WIF-1 (WNT inhibitory factor 1), and lamin A/C.
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histone methyltransferases (e.g., mixed-lineage 
leukemia 1 [MLL1], nuclear-receptor binding SET-
domain protein 1 [NSD1], and nuclear-receptor 
binding SET-domain protein 3 [NSD3]), create ab-
errant fusion proteins.69 In solid tumors, there 
is amplification of genes for histone methyl-
transferases such as EZH2, mixed-lineage leuke-
mia 2 (MLL2), or NSD358,69 or a demethylase (e.g., 
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HMT inhibitors, Sirt1 inhibitors
Clinical drugs:
HDAC inhibitors, DNA demethylating agents
Swi/SNF, HATs, DNMTs, MBDs, Polycomb,
HDACs, HMTs, HDMs, microRNAs
Figure 3. Epigenetic Inactivation of Tumor-Suppressor Genes.
In a normal cell, expression of the mRNA of a tumor-suppressor gene occurs in the context of an unmethylated pro-
moter CpG island and histone modification, such as hyperacetylation and methylation of lysine 4 of histone H3. 
Gray cylinders indicate octamers of histones, consisting of histones H2A, H2B, H3, and H4. They form the nucleo-
somes, and the double strand of DNA is wrapped around them. A combination of selection and targeted disruption 
of the DNA methylation and histone-modifier proteins disrupts the epigenetic circumstances in the cancer cell. Epi-
genetic inactivation of tumor-suppressor genes is associated with dense CpG-island promoter hypermethylation and 
the appearance of repressive histone markers such as methylation of lysines 9 and 27 of histone H3. Epigenetic 
drugs can partially restore the distorted epigenetic picture by removing inactivation markers (e.g., DNA methyla-
tion) and inducing the presence of active markers (e.g., histone acetylation). AC denotes acetylation, DNMTs DNA 
methyltransferases, HATs histone acetyltransferases, HDAC histone deacetylase, HDMs histone demethylases, 
HMTs histone methyltransferases, MBDs methyl-CpG–binding domain proteins, Met-K4 methylation of lysine 4, 
Met-K9 methylation of lysine 9, Met-K27 methylation of lysine 27, Sirt1 sirtuin 1, and Swi/SNF switching/sucrose 
nonfermenting chromatin-remodeling complex.
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Jumonji domain-containing protein 2C [JMJD2C/
GASC1]).70
Epigene tic Fac t or s a nd miR NA
Short, 22-nucleotide, noncoding RNAs that regu-
late gene expression by sequence-specific base pair-
ing in the 3′ untranslated regions of the target 
mRNA are called miRNAs. The result is mRNA 
degradation or inhibition of translation.71 Patterns 
of miRNA expression are tightly regulated and play 
important roles in cell proliferation, apoptosis, and 
differentiation.71 The number of human genes 
known to lose activity as a result of the binding 
of an miRNA to the untranslated regions of the 
mRNA is growing rapidly.72,73
Recent studies have shown that profiles of 
miRNA expression differ between normal tissues 
and tumor tissues and among tumor types.72-74 
Down-regulation of subgroups of miRNAs, a com-
mon finding,72-74 implies a tumor-suppressor func-
tion for miRNAs,72,73 as in the examples of down-
regulated let-7 and miR-15/miR-16, which target the 
RAS and BCL2 oncogenes, respectively.75,76
DNA hypermethylation in the miRNA 5′ regu-
latory region is a mechanism that can account for 
the down-regulation of miRNA in tumors.12,13 In 
colon-cancer cells with disrupted DNMTs, hyper-
methylation of the CpG island does not occur in 
miRNAs.13 The methylation silencing of miR-124a 
also causes activation of the cyclin D–kinase 6 on-
cogene (CDK6),13 and it is a common epigenetic 
lesion in tumors.13
Epigene tic s in C a ncer 
M a nagemen t
The DNA-methylation and histone-modification 
patterns associated with the development and pro-
gression of cancer have potential clinical use. DNA 
hypermethylation markers are under study as com-
plementary diagnostic tools, prognostic factors, 
and predictors of responses to treatment (Fig. 4). 
For instance, the glutathione S-transferase gene 
(GSTP1) is hypermethylated in 80 to 90% of patients 
with prostate cancer,77-79 but it is not hypermeth-
ylated in benign hyperplastic prostate tissue.80 
Thus, the detection of GSTP1 methylation could 
help to distinguish between prostate cancer and a 
benign process. Hypermethylation of CpG islands 
can be a marker of cancer cells in all types of bio-
logic fluids and biopsy specimens,21,81 making 
detection of GSTP1 methylation in urine79,82 a pos-
sible clinical application.
Analysis of hypermethylation of the CpG island 
has potential diagnostic applicability for carriers 
of high-penetrance mutations in tumor-suppressor 
genes. For example, identification of DNA hyper-
methylation in a breast-biopsy specimen from a 
carrier of a BRCA1 mutation could be useful when 
the pathological diagnosis is uncertain, because 
hypermethylation of the CpG island is an early 
event in the development of cancer.56 Analysis of 
several hypermethylated genes detects twice as 
many tumor cells in breast ductal fluids as con-
ventional cytologic analysis,83 and hypermethyl-
ated genes can be found in exfoliated cells at 
different stages in the development of cervical 
cancer.84 The application of DNA-hypermethyl-
ation markers as tumor markers in routine clini-
cal practice will require rapid, quantitative, accu-
rate, and cost-effective techniques and objective 
criteria for selection of the genes that are applica-
ble to different tumor types.
Hypermethylation of a tumor-suppressor gene 
and DNA hypermethylome profiles can be indica-
tors of the prognosis in patients with cancer. Hy-
permethylation of the death-associated protein 
kinase (DAPK), p16INK4a, and epithelial membrane 
protein 3 (EMP3) has been linked to poor out-
comes in lung, colorectal, and brain cancer, re-
spectively.22 Prognostic dendrograms similar to 
those used in gene-expression microarray analy-
ses, with the use of a combination of hypermethyl-
ated markers and CpG-island microarrays, have 
been developed.22 These epigenomic profiles are 
complementary to profiles of gene-expression pat-
terns and can be developed with DNA extracted 
from archived material.21,22
The hypermethylation of particular genes is 
potentially a predictor of the response to treat-
ment. The methylation-associated silencing of the 
gene for the DNA-repair protein MGMT in gliomas 
is an example.85 MGMT reverses the addition of 
alkyl groups to the guanine base of DNA and is 
thus a point of attack for alkylating agents.52 Two 
studies have shown that the hypermethylation of 
MGMT is an independent predictor of a favorable 
response of gliomas to carmustine (BCNU)86 or 
temozolomide.87 These findings have been con-
firmed by others.88 Moreover, the hypermethyl-
ation of MGMT in untreated patents with low-grade 
astrocytoma and other tumor types is a marker of 
a poor prognosis,89,90 and it is probably related to 
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the accumulation of mutations in these tumors.90 
The potential of the methylation status of MGMT 
and other DNA-repair genes to predict the re-
sponse to chemotherapy has also been seen with 
cyclophosphamide (with the MGMT gene),91 cispla-
tin (with the hMLH1 gene),92 methotrexate (with 
the reduced folate carrier [RFC] gene),93 and iri-
notecan (with the WRN gene).53
Epigene tic Ther a py of c a ncer
Unlike mutations, DNA methylation and histone 
modifications are reversible. Epigenetic alterations 
allow the cancer cell to adapt to changes in its mi-
croenvironment, but dormant, hypermethylated 
tumor-suppressor genes can be awakened with 
drugs (Fig. 3). It is possible to re-express DNA-
methylated genes in cancer cell lines by using de-
methylating agents94 and to rescue their function-
ality.22,26 DNA demethylating drugs in low doses 
have clinical activity against some tumors. Two 
such agents, 5-azacytidine (Vidaza) and 5-aza-2′-
deoxycytidine (decitabine), have been approved as 
treatments for the myelodysplastic syndrome and 
leukemia.15,95,96 However, these demethylating 
agents have not yet been shown to have clinical 
activity against solid tumors.15 Histone deacetylase 
(HDAC) inhibitors97 can induce differentiation, 
cell-cycle arrest, and apoptosis in vitro,97 although 
it has not been possible to pinpoint a specific 
mechanism that explains these effects.97,98 In clini-
cal trials, HDAC inhibitors are associated with a 
low incidence of adverse events.15 The first drug of 
this type, suberoylanilide hydroxamic acid (vorino-
stat), has been approved by the Food and Drug Ad-
ministration for the treatment of cutaneous T-cell 
lymphoma.99 The efficacy of HDAC inhibitors in 
the treatment of other tumors is limited.
The nonspecific effects of DNA demethylating 
agents and HDAC inhibitors could have unin-
tended consequences with regard to gene expres-
sion, and as a paradoxical result, they could have 
growth-promoting effects on a tumor. However, 
there are prospects for directed epigenetic-specific 
therapy with the use of transcription factors that 
target particular gene promoters.100 For instance, 
the engineered zinc finger proteins target unique 
sequences in the MASPIN promoter; these proteins 
not only reactivate the epigenetically silenced gene 
but also inhibit tumor growth in vitro.101 Until 
now, therapy with DNA demethylating agents and 
HDAC inhibitors has been based on classic pro-
tein-coding tumor-suppressor genes, but the pos-
sibility of rescuing the growth-inhibitory effects 
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Figure 4. Epigenetics in Cancer Management.
DNA methylation techniques permit the sensitive and quantitative detection of hypermethylated tumor-suppressor genes in all types of 
biologic fluids and biopsy specimens. The establishment of DNA methylation and histone-modification profiles of the primary tumor 
specimen itself might be a valuable tool in determining the prognosis and predicting the patient’s response to therapies.
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of miRNAs by means of DNA-demethylation treat-
ment12,13 suggests new epigenetic treatment strat-
egies that are worthy of further exploration.
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